Enzyme replacement therapy in Niemann-Pik Disease

Background

Niemann-Pick disease types A and B (NPD-A/B) are severe, often fatal, hereditary lysosomal storage disorders characterized by a deficiency in the acid sphingomyelinase (SMase) enzyme. This enzymatic defect leads to the progressive and toxic accumulation of sphingomyelin and other lipids within cells, causing widespread cellular dysfunction and damage to vital organs, including the brain, nerves, liver, and spleen. There is no cure and treatment is limited to symptom management. Existing therapeutic strategies, such as enzyme replacement therapy (ERT) utilizing recombinant ASM, have encountered significant hurdles due to their association with increased inflammatory responses observed in non-human primates, thereby posing a substantial challenge to their clinical applicability.

Technology

Researchers at Stony Brook University and the University of Arizona have developed compositions which increase the lysosomal sphingomyelinase (L-SMase) activity in human subjects. These methods utilize the aSMase-S508A mutant to restore L-SMase activity, thereby addressing Niemann-Pick disease types A and B pathology, while simultaneously preventing the amplified inflammatory response previously observed with recombinant aSMase therapies due to secretory sphingomyelinase (S-SMase) activity.